Drugs / CP003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06739720 | Jan 2025 → Jun 2026 overdue | myalgic encephalomeyelitis/chronic fatigue syndrome, post-COVID-19 disorder | The University of Hong Kong | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP003 | “The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better.” NCT06739720 ↗ |
| Known as | LingZhi capsule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739720 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore...” NCT06739720 ↗ |
| Route | Oral | “Take 5 capsules once daily for 6 weeks” NCT06739720 ↗ |